Passive IgE‐sensitization by blood transfusion

Johansson, S. G. O.; Nopp, Anna; Hage, Marianne van; Olofsson, N; Lundahl, Joachim; Wehlin, Lena; Söderström, Lars; Stiller, V; Öman, H.

doi:10.1111/j.1398-9995.2005.00870.x

Cited by 106 publications

(146 citation statements)

References 23 publications

Supporting

Mentioning

143

Contrasting

Order By: Relevance

“…The observation that basophils passively sensitized in vivo by low amounts specific IgE respond to the appropriate allergen within up to 2 weeks supports this idea. 54 Our data show that spontaneous apoptosis of basophils operates through a caspase-dependent mechanism. It is associated with catalytic processing of caspase 3 into its active form (p17/p12 dimer) and the subsequent cleavage of caspase 3 intracellular substrates, PARP and Bcl-2.…”

mentioning

confidence: 67%

IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils

Didichenko

Spiegl

Brunner

et al. 2008

Blood

104

100

View full text Add to dashboard Cite

IntroductionApoptosis of granulocytes and subsequent clearance of apoptotic cells are important processes for the successful resolution of acute and chronic inflammation. Basophils represent the least abundant granulocyte population and are considered as key effector cells in Th2-type, IgE-associated allergic disorders as well as in protective immune responses to helmints. Pro-inflammatory and immunomodulatory activities of basophils include secretion of histamine and the lipid mediator leukotriene C 4 as well as rapid production of interleukin-4 (IL-4) and IL-13, Th2-type cytokines crucial for the development of allergy and asthma. Positive regulators of basophil mediator release and cytokine production have been described, whereas attempts to find negative regulators of basophil cellular functions have been unsuccessful. Therefore, the modulation of basophil apoptosis probably has a particularly high impact on the outcome of allergic inflammation.Cytokines of granulocyte-macrophage colony-stimulating factor (GM-CSF) subfamily (GM-CSF, IL-5, and IL-3) support granulocyte survival in a granulocyte-type-restricted manner. [1][2][3][4][5][6] Modulation of neutrophil and eosinophil apoptosis mediated by these cytokines has been suggested to rely on the up-regulation of antiapoptotic proteins of the Bcl-2 family, such as Bcl-2, Bcl-X L , Mcl-1 and A1, 7-9 as well as IAP family proteins. [10][11][12] With regards to signaling pathways, Janus kinase (JAK)/signal transducer and activator of transcription 3 and 5 (Stat3/Stat5), phosphatidylinositol 3-kinase (PI3-kinase), as well as p38-mitogen-activated protein kinase (MAPK) have been implicated in the regulation of neutrophil and eosinophil apoptosis by GM-CSF, IL-5, and IL-3. [13][14][15][16][17][18][19] Although previous studies showed that IL-3 prolongs the life span of basophils, 5,6 there is a complete lack of knowledge about the proteins and the mechanisms that regulate spontaneous and cytokineenhanced survival of basophils. A single report suggested a requirement of PI3-kinase signaling for IL-3-mediated basophil survival. 6 The mechanisms of IL-3 signaling and the involvement of downstream targets regulating cell proliferation and survival have been most thoroughly studied in leukemic human cell lines and IL-3-dependent cell lines from genetically manipulated mice. Most papers highlight the requirement of the PI3-kinase/Akt (PKB) signaling pathway and mainly differ in their interpretations about the relative importance of downstream targets, such as Bad, FOXO3, and NF-B. 20-24 These findings cannot always be transferred to human basophils or other nondividing leukocytes because the regulation of survival strongly depends on the cellular background. Furthermore, the mechanisms regulating proliferation or apoptosis are difficult to distinguish in proliferating cells, and transformed cell lines may display disturbed signaling pathways. It is thus necessary to study primary blood basophils ex vivo to understand the mechanisms regulating their survival, despite inhe...

show abstract

mentioning

confidence: 67%

IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils

Didichenko

Spiegl

Brunner

et al. 2008

Blood

104

100

View full text Add to dashboard Cite

show abstract

“…The same group of investigators subsequently performed an in vivo study in which two units (each approximately 300 ml) containing known concentrations of IgE antibodies to timothy grass pollen (8-205 kilo units antigen (kUA)/l) were selected and transfused into patients (Johansson et al, 2005b). IgE in the transfused plasma could be detected in the circulation of the recipients within 3 h after transfusion; the mean half-life of IgE was 1Á13 d. Basophil sensitization was obvious in the 3 h sample, and it increased rapidly to a peak after 3Á4 d and then declined over days to weeks.…”

Section: Passive Sensitizationmentioning

confidence: 99%

Current Understanding of Allergic Transfusion Reactions: Incidence, Pathogenesis, Laboratory Tests, Prevention and Treatment

文也¹

2013

JJTC

View full text Add to dashboard Cite

SummaryNon-haemolytic transfusion reactions are the most common type of transfusion reaction and include transfusion-related acute lung injury, transfusion-associated circulatory overload, allergic reactions, febrile reactions, post-transfusion purpura and graft-versus-host disease. Although life-threatening anaphylaxis occurs rarely, allergic reactions occur most frequently. If possible, even mild transfusion reactions should be avoided because they add to patients' existing suffering. During the last decade, several new discoveries have been made in the field of allergic diseases and transfusion medicine. First, mast cells are not the only cells that are key players in allergic diseases, particularly in the murine immune system. Second, it has been suggested that immunologically active undigested or digested food allergens in a donor's blood may be transferred to a recipient who is allergic to these antigens, causing anaphylaxis. Third, washed platelets have been shown to be effective for preventing allergic transfusion reactions, although substantial numbers of platelets are lost during washing procedures, and platelet recovery after transfusion may not be equivalent to that with unwashed platelets. This review describes allergic transfusion reactions, including the above-mentioned points, and focusses on their incidence, pathogenesis, laboratory tests, prevention and treatment.

show abstract

“…CD‐sens definition: the inverted value for EC50 multiplied by 100 16 . A CD‐sens of <0.1 was regarded as a negative test.…”

Section: Methodsmentioning

confidence: 99%

A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens

Johansson

Lilja

Hallberg

et al. 2018

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionOmalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity and can be used to objectively measure omalizumab treatment efficacy. We aimed to evaluate the effect of omalizumab treatment of allergic asthma by CD‐sens, as an objective marker of the IgE‐mediated inflammation, and related to SPT, spirometry, FeNO, Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE).MethodsThirty‐two patients were treated with omalizumab for 16 weeks. CD‐sens was used to define the response and related to clinical parameters. If CD‐sens was negative (<0.1) (CD‐sens low Group) the patient continued with the standard dose. If CD‐sens was ≥0.1 (CD‐sens high Group) a second 16 weeks period with 25–50% dosage increase was started and evaluated after a total of 32 weeks.ResultsNine of 32 patients became CD‐sens negative after treatment (CD‐sens start: 8.0; 16 weeks: <0.01) and regarded as successful. 15/23 were unsuccessful (CD‐sens start: 13; 16 weeks: 1.65) and the omalizumab dose was increased. CD‐sens decreased significantly (p < 0.05) and further 3/15 patients became CD‐sens negative (CD‐sens at 32 weeks: 0.5). There was a significantly smaller IgE‐ab fraction (IgE‐ab/IgE) in the CD‐sens low versus the CD‐sens high Group (p < 0.0001). A significant decrease in ACQ was seen in both groups after 16 weeks treatment (p = 0.05 and 0.01, respectively). No significant changes could be detected for the other clinical parameters.ConclusionBy the use of the objective laboratory method CD‐sens, which effectively measure the direct effect of omalizumab, that is, the IgE‐mediated part of the allergic asthma, in combination with clinical parameters it might be possible to more effectively monitor and treat IgE‐mediated allergic asthma.

show abstract

Passive IgE‐sensitization by blood transfusion

Cited by 106 publications

References 23 publications

IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils

IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils

Current Understanding of Allergic Transfusion Reactions: Incidence, Pathogenesis, Laboratory Tests, Prevention and Treatment

A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens

Contact Info

Product

Resources

About